Flexible regulatory pathways and key CMC considerations to commercialize cell and gene therapy products
Flexible regulatory pathways and key CMC considerations to commercialize cell and gene therapy products
推动生物制品进入首次人体试验(FIH)首先需要对这些复杂大分子所面临的科学和法规监管挑战的深入了解。从最早期阶段到整个临床开发过程中，需要优先考虑 CMC 指导并精心准备高质量的文件包。

Added Date:

2022-10-16

Filters:

Filter Category Filter Values
Specialty
  • Regulatory
Capability
  • Viral Vectors
Asset Type
  • Webinar on-demand
Expert
  • Monica Commerford PhD
Country
  • All
Region
  • Global
Market Category
  • Advanced therapy

Country Availability:


()

Gated Form:

None Set